Abstract
GPI-15715 (PQ-1002, Aquavan), a water-soluble prodrug of propofol, is being developed by Guilford, under license from ProQuest, as a potential anesthetic agent. In May 2004, Guilford initiated phase III trials in the US to evaluate the sedative effects of this prodrug in several patient populations.
MeSH terms
-
Anesthetics, Intravenous* / adverse effects
-
Anesthetics, Intravenous* / pharmacology
-
Anesthetics, Intravenous* / therapeutic use
-
Animals
-
Clinical Trials as Topic
-
Humans
-
Prodrugs* / adverse effects
-
Prodrugs* / pharmacology
-
Prodrugs* / therapeutic use
-
Propofol* / adverse effects
-
Propofol* / analogs & derivatives*
-
Propofol* / pharmacology
-
Propofol* / therapeutic use
Substances
-
Anesthetics, Intravenous
-
Prodrugs
-
fospropofol
-
Propofol